-

Cordata Announces Back-to-Work COVID Tracking System

CINCINNATI--(BUSINESS WIRE)--Healthcare innovations company Cordata announced today the release of its Back-to-Work (B2W) product offering. The purpose of this offering is to provide employers and organizations the ability to track COVID-19 status, protocols and safety measures.

The B2W tracking system frees key personnel from using tedious spreadsheets and instead leverages Cordata’s proven platform for the management of sensitive information in HIPAA- and ADA-compliant software.

Established in 2014, Cordata has created software solutions backed by its powerful configuration engine to help healthcare providers coordinate care for a wide range of medical specialties. The platform’s inherent flexibility has allowed it to be adapted for other use cases. For instance, today, Cordata’s platform is used by communities around the U.S. to track interventions and outreach to victims of the opioid crisis. With the B2W product, Cordata is extending usage once again to help manage through the COVID-19 crisis, get people back to work and return to interacting socially. B2W can be deployed in a short time frame, is easy-to-learn and scalable.

B2W provides:

  • Assessment and tracking of individuals’ COVID-19 status, protocols and safety measures, including on-location contact-tracing
  • Facilitation of communication to employees about testing or screening required to work in shared/communal facilities
  • Reinforcement of processes and safety through workflows
  • Robust reporting capabilities
  • Simple integrations with other systems

Given the dynamic nature of emerging COVID-19 protocols, the B2W software can be adjusted for new requirements easily without the need for code changes or new deployments.

President and CEO, Gary Winzenread states, “Cordata’s mission is to focus on people and improve results through healthcare technology solutions. Our innovations are uniquely positioned for this moment-in-time to support communities as they work to reopen and restart.”

About Cordata

Our solutions connect people to the treatment and support they need – when, where and how they need it. That includes help in navigating barriers to care and addressing social determinants of health. The goal is not just to help people get better, but ensure they stay better. Our software platform, app, data-driven insights and process templates are designed to help community and healthcare organizations effectively manage their most complex cases – from opioid addiction and behavioral health, to spine, oncology and bariatrics. Across the complete treatment lifecycle, we track outcomes and gather clinical evidence to clarify what works and to improve treatment paths over time. To find out more or how you can leverage the Cordata platform of offerings, visit www.cordatahealth.com.

Contacts

MEDIA INQUIRIES:
c/o: Peg Rusconi
617.910.6217
prusconi@cincytechusa.com

Cordata


Release Summary
Cordata's Back-to-Work (B2W) helps employers keep their workforce healthy with HIPAA-compliant tools to track COVID-19 status, symptoms and protocols.
Release Versions

Contacts

MEDIA INQUIRIES:
c/o: Peg Rusconi
617.910.6217
prusconi@cincytechusa.com

Social Media Profiles
More News From Cordata

CORRECTING and REPLACING Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)

CINCINNATI--(BUSINESS WIRE)--Headline of release should read: Acute Myeloid Leukemia (instead of Acute Myeloid Lymphoma). The updated release reads: KUROME THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KME-0584 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) Entering the clinic in the second half of 2024, KME-0584, an IRAK1/4/panFIt3 Inhibitor is a first in class investigational drug for relapsed/refractory...

Eyas™ Medical Imaging Brings State-of-the-Art MRI to NICUs, Revolutionizing Access for Fragile Newborns

CINCINNATI--(BUSINESS WIRE)--Eyas announces the first for research use only installation of the neonatal MRI system, the Ascent3T™, within the NICU at Cincinnati Children’s....

Invirsa Completes $7.7M Series B Financing

COLUMBUS, Ohio--(BUSINESS WIRE)--Invirsa Inc. has announced the closing of a $7.7 million Series B financing. The financing was led by Ohio-based venture firm, CincyTech....
Back to Newsroom